AI Engines For more Details: Perplexity Kagi Labs You
Contraception: Nomegestrol acetate is often combined with an estrogen component (ethinyl estradiol) to form combined oral contraceptives (COCs). These contraceptive pills are taken daily to prevent pregnancy by suppressing ovulation, thickening cervical mucus to prevent sperm from reaching the egg, and thinning the lining of the uterus to inhibit implantation.
Hormone Replacement Therapy (HRT): Nomegestrol acetate may also be used in hormone replacement therapy for women experiencing menopausal symptoms, such as hot flashes, vaginal dryness, and mood changes. In HRT, nomegestrol acetate is often combined with estrogen to provide relief from menopausal symptoms and prevent osteoporosis.
Endometrial Hyperplasia: Nomegestrol acetate may be prescribed to treat endometrial hyperplasia, a condition characterized by abnormal thickening of the lining of the uterus. By providing progestogenic activity, nomegestrol acetate helps to counteract the proliferative effects of estrogen on the endometrium, thereby reducing the risk of endometrial hyperplasia and associated complications.
Menstrual Disorders: In some cases, nomegestrol acetate may be used to regulate menstrual cycles and treat menstrual disorders such as irregular or heavy menstrual bleeding. By providing a progestogenic effect, nomegestrol acetate can help stabilize the menstrual cycle and reduce menstrual flow.
Androgenic Effects: Nomegestrol acetate has minimal androgenic activity compared to other progestins, which may be beneficial for individuals prone to androgen-related side effects such as acne, hirsutism (excessive hair growth), and alopecia (hair loss).
Cardiovascular Health: Unlike some other progestins, nomegestrol acetate has been associated with favorable effects on lipid metabolism, including increases in high-density lipoprotein (HDL) cholesterol and decreases in low-density lipoprotein (LDL) cholesterol and triglycerides. These lipid profile improvements may contribute to cardiovascular health benefits.
Bone Health: Nomegestrol acetate has been shown to have neutral or positive effects on bone mineral density, which is important for maintaining bone health and reducing the risk of osteoporosis, particularly in postmenopausal women.
Breast Health: There is limited evidence suggesting that nomegestrol acetate may have a neutral or slightly favorable effect on breast tissue compared to other progestins used in hormonal therapy. However, further research is needed to fully understand its impact on breast health.
Adverse Effects: Common side effects associated with nomegestrol acetate-containing medications may include nausea, breast tenderness, headache, mood changes, and breakthrough bleeding or spotting. These side effects are usually mild and tend to improve with continued use.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| ADHD | 1.3 | 1.3 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1.4 | 0.3 | 3.67 |
| Allergies | 1.1 | 0.5 | 1.2 |
| Allergy to milk products | 0.3 | 0.7 | -1.33 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 1.1 | 2.3 | -1.09 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | |
| Ankylosing spondylitis | 1.8 | 0.9 | 1 |
| Anorexia Nervosa | 0.9 | 1.5 | -0.67 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 2.2 | 1.1 | 1 |
| Atherosclerosis | 0.3 | 0.7 | -1.33 |
| Atrial fibrillation | 1.4 | 1.2 | 0.17 |
| Autism | 2.2 | 3.2 | -0.45 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 1 | 0.5 | 1 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Carcinoma | 1.4 | 0.9 | 0.56 |
| Celiac Disease | 0.8 | 1.4 | -0.75 |
| Cerebral Palsy | 0.6 | 1 | -0.67 |
| Chronic Fatigue Syndrome | 1 | 3 | -2 |
| Chronic Kidney Disease | 1 | 1.1 | -0.1 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.1 | -0.22 |
| Chronic Urticaria (Hives) | 0.3 | 0.2 | 0.5 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1 | -0.43 |
| Cognitive Function | 1.6 | 0.8 | 1 |
| Colorectal Cancer | 2.6 | 0.8 | 2.25 |
| Constipation | 0.6 | 0.7 | -0.17 |
| Coronary artery disease | 0.6 | 1 | -0.67 |
| COVID-19 | 3 | 3.9 | -0.3 |
| Crohn's Disease | 2.9 | 1.8 | 0.61 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1 | -1 | |
| deep vein thrombosis | 1.1 | -1.1 | |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 2.9 | 2.9 | 0 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.9 | -0.5 |
| Endometriosis | 1.1 | 0.8 | 0.38 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.7 | 1.6 | -1.29 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 1.8 | 0.5 | 2.6 |
| Functional constipation / chronic idiopathic constipation | 1.5 | 1.6 | -0.07 |
| gallstone disease (gsd) | 0.9 | 0.5 | 0.8 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | -1.2 | |
| Generalized anxiety disorder | 1 | 0.6 | 0.67 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 0.7 | 1.3 | -0.86 |
| Gulf War Syndrome | 0.4 | 0.6 | -0.5 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1 | 0.9 | 0.11 |
| Heart Failure | 1.4 | 0.7 | 1 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.6 | 0.9 | -0.5 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.1 | 2.3 | -0.1 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 1 | 1.8 | -0.8 |
| Inflammatory Bowel Disease | 1.9 | 3.7 | -0.95 |
| Insomnia | 1.3 | 1.5 | -0.15 |
| Intelligence | 0.3 | 0.2 | 0.5 |
| Intracranial aneurysms | 0.9 | 0.9 | |
| Irritable Bowel Syndrome | 2.2 | 1.8 | 0.22 |
| ischemic stroke | 1.1 | 0.8 | 0.38 |
| Liver Cirrhosis | 2.6 | 1.4 | 0.86 |
| Long COVID | 2.3 | 3.3 | -0.43 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.3 | 0.1 | 2 |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | 0.9 | -2 |
| ME/CFS without IBS | 0.6 | 0.9 | -0.5 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 2.8 | 2 | 0.4 |
| Mood Disorders | 2.9 | 2.7 | 0.07 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 1.8 | 2.6 | -0.44 |
| Multiple system atrophy (MSA) | 0.1 | -0.1 | |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 1.6 | -1.6 | |
| Neuropathy (all types) | 0.4 | 1 | -1.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 1.8 | 0 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 2.8 | 2.9 | -0.04 |
| obsessive-compulsive disorder | 1.9 | 1.3 | 0.46 |
| Osteoarthritis | 1 | 0.6 | 0.67 |
| Osteoporosis | 0.8 | 0.7 | 0.14 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 3.1 | 2 | 0.55 |
| Polycystic ovary syndrome | 3.9 | 1.5 | 1.6 |
| Premenstrual dysphoric disorder | 0.1 | 0.4 | -3 |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 1 | 2.1 | -1.1 |
| Psoriasis | 0.4 | 2.1 | -4.25 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 1 | 1.8 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.7 | 1.7 | 0 |
| scoliosis | 0.4 | -0.4 | |
| Sjögren syndrome | 1.1 | 0.9 | 0.22 |
| Sleep Apnea | 0.4 | 1 | -1.5 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 1.3 | 1.3 | 0 |
| Systemic Lupus Erythematosus | 1.7 | 1 | 0.7 |
| Tic Disorder | 0.3 | 0.2 | 0.5 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1 | 1.4 | -0.4 |
| Type 2 Diabetes | 2.3 | 2.3 | 0 |
| Ulcerative colitis | 1.4 | 2.4 | -0.71 |
| Unhealthy Ageing | 1.2 | 1 | 0.2 |
| Vitiligo | 1.3 | 0.4 | 2.25 |
